O6-benzylguanine And Carmustine in Treating Patients With Multiple Myeloma

Inclusion Criteria

• •DISEASE CHARACTERISTICS:
• •Histologically confirmed progressive multiple myeloma, meeting 1 of the following criteria:
• •* Previously untreated
• •* Primary refractory
• •* Relapsing disease
• •Major criteria:
• •* Plasmacytomas on tissue biopsy
• •* Bone marrow plasmacytosis with greater than 30% plasma cells
• •* Monoclonal globulin spike on serum electrophoresis
• •* Greater than 3.5 g/dL for G peaks or greater than 2.0 g for A peaks
• •* Greater than 1.0 g/24 hours of kappa or lambda light chain excretion on urine electrophoresis in the absence of amyloidosis
• •Minor criteria:
• •* 10%-30% bone marrow plasmacytosis (criterion A)
• •* Presence of monoclonal globulin spike but less than the levels under major criteria (criterion B)
• •* Lytic bone lesions (criterion C)
• •* IgM less than 50 mg/dL, IgA less than 100 mg/dL, or IgG less than 600 mg/dL (criterion D)
• •Must meet one of the following:
• •* A minimum of 1 major criterion and 1 minor criterion
• •* 3 minor criteria, including criteria A and B
• •PATIENT CHARACTERISTICS:
• •Age:
• •Not specified
• •Performance status:
• •ECOG 0-2
• •Life expectancy:
• •At least 12 weeks
• •Hematopoietic:
• •WBC greater than 3,000/mm\^3
• •Platelet count greater than 100,000/mm\^3
• •Absolute neutrophil count greater than 1,500/mm\^3
• •Hemoglobin greater than 9 g/dL (transfusions allowed)
• •Hepatic:
• •Bilirubin less than 1.5 mg/dL
• •AST/ALT less than 2 times normal
• •Renal:
• •Creatinine no greater than 2.0 mg/dL OR
• •Creatinine clearance greater than 60 mL/min
• •Calcium less than 14 mg/dL
• •Pulmonary:
• •No prior or concurrent active, symptomatic respiratory disease
• •Corrected DLCO at least 60% predicted
• •Other:
• •Controlled diabetes mellitus allowed
• •Not pregnant or nursing
• •Negative pregnancy test
• •Fertile patients must use effective contraception during and for 2 months after study participation
• •PRIOR CONCURRENT THERAPY:
• •Biologic therapy:
• •Not specified
• •Chemotherapy:
• •No more than 1 prior chemotherapy regimen containing an alkylating agent for multiple myeloma
• •At least 4 weeks since prior chemotherapy
• •Endocrine therapy:
• •Prior corticosteroids for multiple myeloma allowed
• •Radiotherapy:
• •No prior pelvic radiotherapy or radiotherapy to more than 25% of bone marrow
• •Surgery:
• •Not specified